A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight (STEP Young)
Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight
Sponsor: Novo Nordisk A/S
A observational or N/A phase clinical study on Obesity, this trial is ongoing. The trial is conducted by Novo Nordisk A/S and has accumulated 22 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
22 versions recorded-
Apr 28, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE3 → None
-
Dec 2025 — Apr 2026 [monthly]
Active Not Recruiting PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 17 earlier versions
-
Dec 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults. The child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .